Drug ResearchPub Date : 2023-07-01DOI: 10.1055/a-2062-3571
Lauro Figueroa-Valverde, Francisco Díaz-Cedillo, Marcela Rosas-Nexticapa, Magdalena Alvarez-Ramirez, Maria Virginia Mateu-Armad, Maria López-Ramos, Tomas López-Gutierrez
{"title":"Interaction of Some Amino-Nitrile Derivatives with Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Using a Theoretical Model.","authors":"Lauro Figueroa-Valverde, Francisco Díaz-Cedillo, Marcela Rosas-Nexticapa, Magdalena Alvarez-Ramirez, Maria Virginia Mateu-Armad, Maria López-Ramos, Tomas López-Gutierrez","doi":"10.1055/a-2062-3571","DOIUrl":"https://doi.org/10.1055/a-2062-3571","url":null,"abstract":"<p><strong>Background: </strong>Some studies indicate that the angiogenesis process is related to vascular endothelial growth factor, which can interact with endothelial cell surface receptors (VEGF-R1, VEGF-R2, and VEGF-R3); this biochemical process and other factors result in the promotion and growth of new blood vessels under normal conditions. However, some studies indicate that this phenomenon could also occur in cancer cells. It is important to mention that some amino derivatives have been prepared as VEGF-R1 inhibitors; however, their interaction with VEGF-R1 is not clear, perhaps due to different experimental approaches or differences in their chemical structure.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the theoretical interaction of several amino-nitrile derivatives (Compounds 1 to 38) with VEGF-R1.</p><p><strong>Methods: </strong>The theoretical interaction of amino-nitrile derivatives with VEGF-R1 was carried out using the 3hng protein as the theoretical model. In addition, cabozantinib, pazopanib, regorafenib, and sorafenib were used as controls in the DockingServer program.</p><p><strong>Results: </strong>The results showed different amino acid residues involved in the interaction of amino-nitrile derivatives with the 3hng protein surface compared with the controls. In addition, the inhibition constant (Ki) was lower for Compounds 10 and 34 than for cabozantinib. Other results show that Ki for Compounds 9, 10, 14, 27-29 and 34-36 was lower in comparison with pazopanib, regorafenib, and sorafenib.</p><p><strong>Conclusions: </strong>All theoretical data suggest that amino-nitrile derivatives could produce changes in the growth of some cancer cell lines through VEGFR-1 inhibition. Therefore, these amino-nitrile derivatives could be a therapeutic alternative to treat some types of cancer.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"355-364"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9783726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-07-01DOI: 10.1055/a-2061-7129
Deepa Neopane, Vaseem Ahamad Ansari, Aditya Singh
{"title":"Ferulic Acid: Signaling Pathways in Aging.","authors":"Deepa Neopane, Vaseem Ahamad Ansari, Aditya Singh","doi":"10.1055/a-2061-7129","DOIUrl":"https://doi.org/10.1055/a-2061-7129","url":null,"abstract":"<p><p>The need for clinical remedies to the multiple age-related deficiencies in skin function brought on by extrinsic and intrinsic causes is increased by these demographic changes. Reactive oxygen species (ROS), mitochondrial deoxyribonucleic acid (mtDNA) mutations, telomere shortening, as well as other factors, contribute to the aging of the skin. In this overview, the issue of human skin aging is introduced, along with several pathways and the protective effects of ferulic acid in light of current patents. The complex antioxidant effect of ferulic acid depends on the \"sweeping\" away of free radicals as well as the suppression of the synthesis of ROS or nitrogen. Furthermore, Cu (II) or Fe protonated metal ions are chelated by this acid (II). Ferulic acid is a free radical scavenger as well as an enzyme inhibitor, increasing the activity of enzymes that scavenge free radicals while decreasing the activity of enzymes that speed up the creation of free radicals. AMPK signalling, which can regulate cellular homeostasis, stress tolerance, cell survival and proliferation, cell death, and autophagy, has recently been linked to aging and lifespan. Therefore, Caenorhabditis elegans (C. elegans) and rodents had longer life-spans due to specific AMPK activation. By inhibiting the TGF-β/Smad signalling pathway, UV irradiation can reduce the production of procollagen. Glycation changes the skin's physical characteristics, making it less elastic and stiffer. . Excessive free radicals simultaneously trigger the nuclear factor kappa B (NF- κB) signalling pathway, increasing TNF levels and matrix metalloproteinase production (MMPs).</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"318-324"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10170366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-07-01DOI: 10.1055/a-2004-3591
Sabreena Naz, Tarique Mahmood, Ramesh Gupta, Mohammed Haris Siddiqui, Farogh Ahsan, Vaseem Ahamad Ansari, Arshiya Shamim, Ali Abbas Rizvi
{"title":"Clinical Manifestation of AGE-RAGE Axis in Neurodegenerative and Cognitive Impairment Disorders.","authors":"Sabreena Naz, Tarique Mahmood, Ramesh Gupta, Mohammed Haris Siddiqui, Farogh Ahsan, Vaseem Ahamad Ansari, Arshiya Shamim, Ali Abbas Rizvi","doi":"10.1055/a-2004-3591","DOIUrl":"https://doi.org/10.1055/a-2004-3591","url":null,"abstract":"<p><p>The receptor of Advanced Glycation Endproducts (RAGE) and Advanced Glycation Endproducts (AGE) have multiple functions in our body and their restraint are being observed in neurodegenerative and memory impairment disorders. The review of different pathways allows an understanding of the probable mechanism of neurodegeneration and memory impairment involving RAGE and AGE. Commonly we observe AGE accumulation in neural cells and tissues but the extent of accumulation increases with the presence of memory impairment disorder. The presence of AGEs can also be seen in morbid accumulation, pathological structures in the form of amyloid clots, and nervous fibrillary tangles in Alzheimer's Disease (AD) and memory impairment disease.Many neuropathological and biochemical aspects of AD are explained by AGEs, including widespread protein crosslinking, glial activation of oxidative stress, and neuronal cell death. Oxidative stress is due to different reasons and glycation end products set in motion and form or define various actions which are normally due to AGE changes in a pathogenic cascade. By regulating the transit of ß-amyloid in and out of the brain or altering inflammatory pathways, AGE and it's ensnare receptor such as soluble RAGE may function as blockage or shield AD development. RAGE activates the transcription-controlling factor Necrosis Factor (NF-κB) and increases the protraction of cytokines, like a higher number of Tumor Necrosis Factor (TNF-α) and Interleukin (IL-I) by inducing several signal transduction cascades. Furthermore, binding to RAGE can pro-activate reactive oxygen species (ROS), which is popularly known to cause neuronal death.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"309-317"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9792871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2.","authors":"Sunil Kumar Patnaik, Akey Krishna Swaroop, Mudavath Ravi Naik, Jubie Selvaraj, Moola Joghee Nanjan Chandrasekar","doi":"10.1055/a-2030-4078","DOIUrl":"https://doi.org/10.1055/a-2030-4078","url":null,"abstract":"<p><p>ErbB1 and ErbB2 are the most important biological targets in cancer drug discovery and development of dual inhibitors for the cancer therapy. FDA approved drugs and Neuropep peptides were used to fit into the ATP binding site of the tyrosine kinases; ErbB1 and ErbB2 proteins. Cytoscape, iGEMDOCK, HPEPDOCK and DataWarrior softwares were used to study the role of these agents as anticancer drugs. Eleven FDA approved drugs and eleven Neuropep peptides showed the strongest 2D interactions and significant binding energy with the proteins. <i>Invitro</i> MTT anticancer assay revealed that, the test compounds, peptide YSFGL and doxorubicin showed significant IC<sub>50</sub> value (µM) of 26.417±0.660 and 7.675±0.278 respectively which are compared with the lapatinib standard IC<sub>50</sub> value (µM) of 2.380±0.357 against A549 cells and IC<sub>50</sub> value (µM) of 39.047±0.770 and 8.313±0.435 respectively which are compared with the lapatinib standard IC<sub>50</sub> value (µM) of 3.026±0.180 against MDA-MB-231 cells.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"341-348"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9781531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-07-01DOI: 10.1055/a-2007-1820
Guo Haihua, Zhang Rui, Deng Liangjun, Li Meng, Li Sha, Zhao Suqing
{"title":"HPLC-UV/VIS for Determination of Ipratropium Bromide Mixed with Salbuterol, Beclomethasone Propionate and Budesonide using Dual Wavelength-Detection Method.","authors":"Guo Haihua, Zhang Rui, Deng Liangjun, Li Meng, Li Sha, Zhao Suqing","doi":"10.1055/a-2007-1820","DOIUrl":"https://doi.org/10.1055/a-2007-1820","url":null,"abstract":"<p><strong>Background: </strong>Inhalation preparation involves liquid or solid raw materials for delivering to lungs as aerosol or vapor. The liquid preparation for nebulizer is effective for convenient use and patient compliance and it has been extensively used in the treatment of clinical lung diseases. Clinical staff often mixes the compound ipratropium bromide with beclomethasone propionate and budesonide inhaler but reference values of inhalants for clinical use need to be established for simplifying the operation procedure. The high-performance liquid chromatography (HPLC) method of compound ipratropium bromide solution, beclomethasone propionate suspension and budesonide suspension after mixed atomization was studied.</p><p><strong>Methods: </strong>The specificity, linearity, recovery (accuracy), precision and stability of compound ipratropium bromide, beclomethasone propionate and budesonide were tested to verify the developed liquid phase method.</p><p><strong>Results: </strong>The developed liquid phase method had high specificity, linear R2≥0,999, recovery (accuracy) RSD (relative standard deviation) less than 2%, precision RSD less than 2,0%, and stability RSD less than 2,0%.</p><p><strong>Conclusion: </strong>The liquid phase methodology developed in this study can be used for the determination of compound ipratropium bromide mixed with beclomethasone propionate and budesonide. The current methodology can also be used to provide a reference for the determination of its content after mixing, and further data support for its clinical medication.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"335-340"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10145861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-07-01DOI: 10.1055/a-2024-9964
Shilpa Jain, Monika Datta
{"title":"Pluronic F-68 Montmorillonite As A Drug Delivery Vehicle For Extended Release Of Venlafaxine Hydrochloride.","authors":"Shilpa Jain, Monika Datta","doi":"10.1055/a-2024-9964","DOIUrl":"https://doi.org/10.1055/a-2024-9964","url":null,"abstract":"<p><p>Short half-life and low bioavailability of Venlafaxine hydrochloride (VF), an antidepressant drug, necessitates the frequent administration of VF tablets in a day in order to maintain adequate drug concentration in blood plasma. This generates the need for the development of formulations which could prolong the release of VF and reduce the multiple dosages. The present work explores the combination of Montmorillonite (Mt) with Pluronic F-68 (PF-68) (OrganoMT) for oral delivery of VF. The effect of various parameters including pH of aqueous drug solution, contact time and initial drug concentration on drug loading capacity of OrganoMT has been studied. The synthesized OrganoMT-VF complexes were characterized by various suitable techniques. XRD studies indicated that the VF molecules were intercalated within the OrganoMT layers. In vitro release behavior of VF from OrganoMT-VF complexes shows an extended-release pattern for a period of 30 h and reaches upto 70% and 60% compared to pure VF having complete release time of 5.5 h and 3.5 h in simulated gastric and intestinal fluid respectively. Various kinetic models were employed to elucidate the drug release mechanism where the best fitting was obtained with Korsmeyer Peppas model. The results suggest the possibility of designing an oral extended controlled release formulation for VF to minimize its administration frequency thereby increasing the effectiveness of drug. This improves patient compliance by reducing the dose from 4 times in 24 h to once in 24 h.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"325-334"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9782613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-07-01DOI: 10.1055/a-2061-7074
Ehab R Bendas, Mamdouh R Rezk, Kamal A Badr
{"title":"Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation.","authors":"Ehab R Bendas, Mamdouh R Rezk, Kamal A Badr","doi":"10.1055/a-2061-7074","DOIUrl":"https://doi.org/10.1055/a-2061-7074","url":null,"abstract":"<p><p>Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release tablets. In vitro dissolution testing was investigated for favipiravir tablets in three different pH media. The pharmacokinetic features of favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter \"AUC0-t\" vs. percent dissolved was used to develop level C in vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro release results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmax of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. Level C IVIVC was developed successfully. It was concluded that Egyptian volunteers had comparable Pk values to American and Caucasian volunteers, however they were considerably different from Japanese subjects. AUC0-t vs. % dissolved was used to develop level C IVIVC to set the optimum dissolution medium. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 6","pages":"349-354"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9788742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-06-01Epub Date: 2023-03-27DOI: 10.1055/a-1982-3811
Kuspuji Dwitanto, Nova Angginy, Widodo Sutandar
{"title":"Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney Disease) Patients.","authors":"Kuspuji Dwitanto, Nova Angginy, Widodo Sutandar","doi":"10.1055/a-1982-3811","DOIUrl":"10.1055/a-1982-3811","url":null,"abstract":"<p><strong>Purpose: </strong>This study was conducted to evaluate whether the efficacy and safety profile of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.</p><p><strong>Patients and methods: </strong>It was an open-label, randomized, comparative, parallel, multi-center study in hemodialysis patients with anemia. The reference product at an individualized dose 3 times a week was given in 4-8 weeks of titration period and hemoglobin (Hb) level was controlled to reach the range of 10-12 g/dL. Then, the subjects were randomly administered with reference or test product with the same dose regimen. The primary endpoints were to demonstrate the Hb level change between baseline and evaluation period in both treatment groups, while the secondary endpoints were the mean change in weekly dosage per kg body weight and the instability rate of Hb level during maintenance and evaluation period. The safety was evaluated based on the adverse events incidence.</p><p><strong>Results: </strong>There was no statistical difference in the change of Hb between test and reference (0.14 g/dL and 0.75 g/dL respectively, with p>0.05), also for the mean changes of weekly dosage between groups (1091.40 IU and 570.15 IU respectively, with p>0.05). The instability rate of Hb in both test and reference was not statistically significantly different as well (26 and 15% respectively, with p>0.05).</p><p><strong>Conclusion: </strong>This study proves that the efficacy indicated by the change instability of Hb and safety indicated by adverse event incidence of Epodion and the reference product on chronic kidney disease were similar.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 5","pages":"271-278"},"PeriodicalIF":1.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/31/10-1055-a-1982-3811.PMC10241559.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9582746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-06-01DOI: 10.1055/a-1995-6351
Lauro Figueroa-Valverde, Marcela Rosas-Nexticapa, Magdalena Alvarez-Ramirez, Maria López-Ramos, Francisco Díaz-Cedillo, Maria Virginia Mateu-Armad
{"title":"Evaluation of Biological Activity Exerted by Dibenzo[b,e]Thiophene-11(6H)-One on Left Ventricular Pressure Using an Isolated Rat Heart Model.","authors":"Lauro Figueroa-Valverde, Marcela Rosas-Nexticapa, Magdalena Alvarez-Ramirez, Maria López-Ramos, Francisco Díaz-Cedillo, Maria Virginia Mateu-Armad","doi":"10.1055/a-1995-6351","DOIUrl":"https://doi.org/10.1055/a-1995-6351","url":null,"abstract":"<p><strong>Background: </strong>Some studies show that some Dibenzo derivatives can produce changes in the cardiovascular system; however, its molecular mechanism is not very clear.</p><p><strong>Objective: </strong>The objective of this investigation was to evaluate the inotropic activity of ten Dibenzo derivatives (compounds 1 to 10) on either perfusion pressure or left ventricular pressure.</p><p><strong>Methods: </strong>Biological activity produced by the Dibenzo derivatives on either perfusion pressure or coronary resistance was evaluated using an isolated rat heart. In addition, the molecular mechanism of biological activity produced by compound 4 (Dibenzo[b,e]thiophene-11(6H)-one) on left ventricular pressure was determined using both Bay-k8644 and nifedipine as pharmacological tools in an isolated rat heart model.</p><p><strong>Results: </strong>The results showed that Dibenzo[b,e]thiophene-11(6H)-one increases perfusion pressure and coronary resistance at a dose of 0.001 nM. Besides, other data display that Dibenzo[b,e]thiophene-11(6H)-one increases left ventricular pressure in a dose-dependent manner (0.001 to 100 nM) and this effect was similar to biological activity produced by Bay-k8644 drug on left ventricular pressure. However, the effect exerted by Dibenzo[b,e]thiophene-11(6H)-one was inhibited in the presence of nifedipine at a dose of 1 nM.</p><p><strong>Conclusions: </strong>All these data suggest that Dibenzo[b,e]thiophene-11(6H)-one increase left ventricular pressure through calcium channel activation. In this way, Dibenzo[b,e]thiophene-11(6H)-one could be a good candidate as positive inotropic agent to heart failure.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 5","pages":"263-270"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9953526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2023-06-01DOI: 10.1055/a-2015-8041
Aditya Singh, Vaseem Ahamad Ansari, Tarique Mahmood, Farogh Ahsan, Rufaida Wasim, Mohammad Shariq, Saba Parveen, Shubhrat Maheshwari
{"title":"Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment.","authors":"Aditya Singh, Vaseem Ahamad Ansari, Tarique Mahmood, Farogh Ahsan, Rufaida Wasim, Mohammad Shariq, Saba Parveen, Shubhrat Maheshwari","doi":"10.1055/a-2015-8041","DOIUrl":"https://doi.org/10.1055/a-2015-8041","url":null,"abstract":"<p><p>The pathophysiological processes of dementia and cognitive impairment are linked to advanced glycation end products (AGEs) and their receptor (RAGE).The neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau protein and senile plaques (SPs), which are brought on by amyloid beta (Aβ) deposition, are the hallmarks of Alzheimer's disease (AD), a progressive neurodegenerative condition. Advanced glycation end products that are produced as a result of vascular dysfunction are bound by the receptor for advanced glycation end products (RAGE). Dementia and cognitive impairment could develop when RAGE binds to Aβ and produces reactive oxygen species, aggravating Aβ buildup and ultimately resulting in SPs and NFTs. RAGE could be a more powerful biomarker than Aβ because it is implicated in early AD. The resident immune cells in the brain known as microglia are essential for healthy brain function. Microglia is prominent in the amyloid plaques' outside border as well as their central region in Alzheimer's disease. Microglial cells, in the opinion of some authors, actively contribute to the formation of amyloid plaques. In this review, we first discuss the early diagnosis of dementia and cognitive impairment, and then detail the interaction between RAGE and Aβ and Tau that is necessary to cause dementia and cognitive impairment pathology, and it is anticipated that the creation of RAGE probes will help in the diagnosis and treatment of dementia and cognitive impairment.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 5","pages":"247-250"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10008441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}